Medicamen Organics (NSE:MEDIORG) EBITDA Margin % : 16.64% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Medicamen Organics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medicamen Organics's EBITDA for the six months ended in Mar. 2024 was ₹23.2 Mil. Medicamen Organics's Revenue for the six months ended in Mar. 2024 was ₹139.5 Mil. Therefore, Medicamen Organics's EBITDA margin for the quarter that ended in Mar. 2024 was 16.64%.

Medicamen Organics EBITDA Margin % Historical Data

The historical data trend for Medicamen Organics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicamen Organics EBITDA Margin % Chart

Medicamen Organics Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

EBITDA Margin %

6.45

6.54

11.91

18.72

Medicamen Organics Semi-Annual Data
	Mar21	Mar22	Mar23	Sep23	Mar24
EBITDA Margin %	-	-	-	21.29	16.64

Competitive Comparison of Medicamen Organics's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Medicamen Organics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicamen Organics's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicamen Organics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Medicamen Organics's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

Medicamen Organics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Medicamen Organics's EBITDA Margin % for the fiscal year that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Mar. 2024 )	/	Revenue (A: Mar. 2024 )
	=	47.32	/	252.717
	=	18.72 %

Medicamen Organics's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	23.217	/	139.517
	=	16.64 %

Medicamen Organics (NSE:MEDIORG) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Medicamen Organics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Medicamen Organics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicamen Organics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicamen Organics Ltd (NSE:MEDIORG) » Definitions » EBITDA Margin %

Traded in Other Exchanges

N/A

Address

Ashok Vihar Phase II, 10, Community Center No. 2, New Delhi, IND, 110052

Website

https://www.medicamenorganics.com

Medicamen Organics Ltd is engaged in developing, manufacturing, and distribution of broad range of pharmaceutical dosages including generic dosages in the form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders for government and private institutions as contract manufacturer/third party manufacturer. The company markets its product to private pharma companies in domestic as well as international markets through third-party distributors or on a loan license basis.

Medicamen Organics Headlines

No Headlines